Redhill Biopharma Ltd. (NASDAQ:RDHL) Stock Short Interest Report for October

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 61,151 shares, a decrease of 52.3% from the October 15th total of 128,328 shares. Based on an average daily volume of 132,590 shares, the short-interest ratio is currently 0.5 days. Approximately 0.7% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 6th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Redhill Biopharma presently has an average rating of “Sell”.

Redhill Biopharma Trading Down 1.6%

RDHL traded down $0.01 on Friday, hitting $0.38. 35,193 shares of the stock traded hands, compared to its average volume of 106,631. The business has a fifty day moving average price of $0.50 and a two-hundred day moving average price of $0.77. Redhill Biopharma has a 52 week low of $0.36 and a 52 week high of $1.60.

About Redhill Biopharma

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious diseases. The company was founded in Israel and later operated as a publicly traded company in the United States under the ticker symbol RDHL. RedHill’s principal commercial product was Talicia, an oral combination of omeprazole, amoxicillin and rifabutin approved by the U.S. Food and Drug Administration for the treatment of Helicobacter pylori infection in adults.